ATE503482T1 - Verwendung von pirlindol bei der behandlung von erkrankungen; die durch proliferation von t- lymphozyten und/oder hyperproliferation von keratinozyten gekennzeichnet sind; insbesondere atopische dermatitis und psoriasis - Google Patents
Verwendung von pirlindol bei der behandlung von erkrankungen; die durch proliferation von t- lymphozyten und/oder hyperproliferation von keratinozyten gekennzeichnet sind; insbesondere atopische dermatitis und psoriasisInfo
- Publication number
- ATE503482T1 ATE503482T1 AT05798339T AT05798339T ATE503482T1 AT E503482 T1 ATE503482 T1 AT E503482T1 AT 05798339 T AT05798339 T AT 05798339T AT 05798339 T AT05798339 T AT 05798339T AT E503482 T1 ATE503482 T1 AT E503482T1
- Authority
- AT
- Austria
- Prior art keywords
- hyperproliferation
- keratinocytes
- psoriasis
- pirlindol
- lymphocytes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04025961A EP1688161A1 (de) | 2004-11-02 | 2004-11-02 | Verwendung von pirlindol zur Behandlung der Krankheiten gekennzeichnet durch Proliferation von t-Lymphozyten und/oder Hyperproliferation von Keratinozyten, ins besondere atopischer Dermatitis und Psoriasis |
| PCT/EP2005/011697 WO2006048242A2 (en) | 2004-11-02 | 2005-11-02 | Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE503482T1 true ATE503482T1 (de) | 2011-04-15 |
Family
ID=34927197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05798339T ATE503482T1 (de) | 2004-11-02 | 2005-11-02 | Verwendung von pirlindol bei der behandlung von erkrankungen; die durch proliferation von t- lymphozyten und/oder hyperproliferation von keratinozyten gekennzeichnet sind; insbesondere atopische dermatitis und psoriasis |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20080254106A1 (de) |
| EP (2) | EP1688161A1 (de) |
| JP (1) | JP2008518891A (de) |
| AT (1) | ATE503482T1 (de) |
| AU (1) | AU2005300727B2 (de) |
| CA (1) | CA2585536A1 (de) |
| DE (1) | DE602005027232D1 (de) |
| DK (1) | DK1807083T3 (de) |
| ES (1) | ES2363019T3 (de) |
| WO (1) | WO2006048242A2 (de) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1688161A1 (de) * | 2004-11-02 | 2006-08-09 | Switch Biotech Aktiengesellschaft | Verwendung von pirlindol zur Behandlung der Krankheiten gekennzeichnet durch Proliferation von t-Lymphozyten und/oder Hyperproliferation von Keratinozyten, ins besondere atopischer Dermatitis und Psoriasis |
| JP2012502915A (ja) | 2008-09-15 | 2012-02-02 | バイオビスタ インコーポレイテッド | てんかんを治療する組成物及び方法 |
| WO2010068867A1 (en) * | 2008-12-11 | 2010-06-17 | Biovista, Inc. | Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles |
| ES2564502T3 (es) | 2010-03-17 | 2016-03-23 | Novaliq Gmbh | Composición farmacéutica para el tratamiento de la presión intraocular aumentada |
| EP2444063A1 (de) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Flüssige pharmazeutische Zusammensetzungen zur Abgabe von Wirkstoffen |
| EP2462921A1 (de) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Flüssige pharmazeutische Zusammensetzungen zur Behandlung einer Erkrankung der Hinterseite des Auges |
| JP2014511393A (ja) * | 2011-03-07 | 2014-05-15 | セルジーン コーポレイション | イソインドリン化合物を用いた疾患の治療方法 |
| JP6039145B2 (ja) * | 2011-05-25 | 2016-12-07 | ノバリック ゲーエムベーハー | 半フッ化アルカンを基礎にした局所薬学的組成物 |
| JP6023181B2 (ja) * | 2011-05-25 | 2016-11-09 | ノバリック ゲーエムベーハー | 爪に投与するための医薬組成物 |
| WO2013070526A1 (en) * | 2011-11-09 | 2013-05-16 | Teikoku Pharma Usa, Inc. | Methods for the treatment of skin neoplasms |
| US20150018362A1 (en) | 2012-02-27 | 2015-01-15 | Biovista, Inc. | Compositions and methods for treating mitochondrial diseases |
| IN2014DN11181A (de) * | 2012-07-04 | 2015-10-02 | Univ Sydney | |
| DE202013012753U1 (de) | 2012-09-12 | 2019-03-04 | Novaliq Gmbh | Zusammensetzungen semifluorierter Alkane zur Verwendung in der Behandlung von Keratoconjunctivitis Sicca |
| MX360469B (es) | 2012-09-12 | 2018-11-05 | Novaliq Gmbh | Composiciones que comprenden mezclas de alcanos semifluorados. |
| MX2015008129A (es) * | 2012-12-19 | 2015-09-23 | Polichem Sa | Uso de pidotimod para tratar la dermatitis atopica. |
| UA116499C2 (uk) * | 2014-05-09 | 2018-03-26 | Текнімеді Сос'Єдаді Текніку-Медісінал С.А. | (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині |
| UA118587C2 (uk) | 2014-05-09 | 2019-02-11 | Текнімеді Сос'Єдаді Текніку-Медісінал С.А. | Фармацевтично прийнятні солі енантіомерів пірліндолу для застосування в медицині |
| TN2016000498A1 (en) * | 2014-05-09 | 2018-04-04 | Tecnimede Sociedade Tecnico Medicinal S | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine. |
| ES2953837T3 (es) | 2015-09-30 | 2023-11-16 | Novaliq Gmbh | 2-perfluorobutil pentano para administración oftálmica |
| CN120884568A (zh) | 2015-09-30 | 2025-11-04 | 诺瓦利克有限责任公司 | 半氟化化合物和其组合物 |
| EP3442480B1 (de) | 2016-06-23 | 2019-10-02 | Novaliq GmbH | Verfahren zur topischen verabreichung |
| US11684589B2 (en) | 2016-09-22 | 2023-06-27 | Novaliq Gmbh | Pharmaceutical compositions for use in the therapy of blepharitis |
| JP6869336B2 (ja) | 2016-09-23 | 2021-05-12 | ノバリック ゲーエムベーハー | シクロスポリンを含む眼科用組成物 |
| DK3399962T3 (da) | 2016-12-23 | 2020-09-07 | Novaliq Gmbh | Oftalmisk sammensætning til behandling af tør øjensygdom |
| MX388460B (es) | 2017-04-21 | 2025-03-20 | Dermaliq Therapeutics Inc | Composiciones de yodo. |
| CN110650734B (zh) | 2017-05-12 | 2024-11-15 | 诺瓦利克有限责任公司 | 治疗与隐形眼镜有关病症的包含半氟化烷烃的药物组合物 |
| IL273531B2 (en) | 2017-09-27 | 2024-05-01 | Novaliq Gmbh | Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases |
| US11896559B2 (en) | 2017-10-04 | 2024-02-13 | Novaliq Gmbh | Opthalmic compositions comprising F6H8 |
| EP3758676A1 (de) | 2018-03-02 | 2021-01-06 | Novaliq GmbH | Pharmazeutische zusammensetzungen mit nebivolol |
| JP2021522219A (ja) | 2018-04-27 | 2021-08-30 | ノバリック ゲーエムベーハー | 緑内障の治療のためのタフルプロストを含む眼科用組成物 |
| US12029757B2 (en) | 2018-09-27 | 2024-07-09 | Dermaliq Therapeutics, Inc. | Lipid barrier repair |
| JP7292567B2 (ja) | 2018-09-27 | 2023-06-19 | ダーマリック セラピューティクス， インコーポレーテッド | 局所日焼け止め製剤 |
| WO2020074697A1 (en) | 2018-10-12 | 2020-04-16 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| WO2020165132A1 (en) | 2019-02-13 | 2020-08-20 | Novaliq Gmbh | Compositions and methods for the treatment of ocular neovascularization |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY110603A (en) * | 1993-05-27 | 1998-08-29 | Novartis Ag | Tetrahydropyran derivatives |
| US5922341A (en) * | 1997-10-28 | 1999-07-13 | Vivus, Incorporated | Local administration of pharmacologically active agents to treat premature ejaculation |
| US6514696B1 (en) * | 1997-11-13 | 2003-02-04 | The Regents Of The University Of California | Transcriptionally regulated G protein-coupled receptor G2A |
| AU2002331064B2 (en) * | 2001-08-10 | 2007-08-23 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
| US7132415B2 (en) * | 2001-09-21 | 2006-11-07 | Schering Corporation | Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors |
| WO2004039320A2 (en) * | 2002-10-25 | 2004-05-13 | Collegium Pharmaceutical, Inc. | STEREOISOMERS OF p-HYDROXY-MILNACIPRAN, AND METHODS OF USE THEREOF |
| DE50304744D1 (de) * | 2003-04-28 | 2006-10-05 | Biofrontera Bioscience Gmbh | Verwendung von Riluzole kombiniert mit geeigneten Hilfs-und Zusatzstoffen zur Behandlung von Krankheiten, die durch eine Hyperproliferation von Keratinozyten gekennzeichnet sind, insbesondere Neurodermitis und Psoriasis |
| EP1688161A1 (de) * | 2004-11-02 | 2006-08-09 | Switch Biotech Aktiengesellschaft | Verwendung von pirlindol zur Behandlung der Krankheiten gekennzeichnet durch Proliferation von t-Lymphozyten und/oder Hyperproliferation von Keratinozyten, ins besondere atopischer Dermatitis und Psoriasis |
-
2004
- 2004-11-02 EP EP04025961A patent/EP1688161A1/de not_active Withdrawn
-
2005
- 2005-11-02 EP EP05798339A patent/EP1807083B1/de not_active Expired - Lifetime
- 2005-11-02 AT AT05798339T patent/ATE503482T1/de active
- 2005-11-02 CA CA002585536A patent/CA2585536A1/en not_active Abandoned
- 2005-11-02 JP JP2007538355A patent/JP2008518891A/ja active Pending
- 2005-11-02 DE DE602005027232T patent/DE602005027232D1/de not_active Expired - Lifetime
- 2005-11-02 WO PCT/EP2005/011697 patent/WO2006048242A2/en not_active Ceased
- 2005-11-02 ES ES05798339T patent/ES2363019T3/es not_active Expired - Lifetime
- 2005-11-02 US US11/718,476 patent/US20080254106A1/en not_active Abandoned
- 2005-11-02 AU AU2005300727A patent/AU2005300727B2/en not_active Ceased
- 2005-11-02 DK DK05798339.7T patent/DK1807083T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008518891A (ja) | 2008-06-05 |
| WO2006048242A2 (en) | 2006-05-11 |
| WO2006048242A3 (en) | 2006-11-09 |
| AU2005300727B2 (en) | 2010-07-15 |
| CA2585536A1 (en) | 2006-05-11 |
| EP1807083A2 (de) | 2007-07-18 |
| US20080254106A1 (en) | 2008-10-16 |
| AU2005300727A1 (en) | 2006-05-11 |
| EP1807083B1 (de) | 2011-03-30 |
| DE602005027232D1 (de) | 2011-05-12 |
| ES2363019T3 (es) | 2011-07-18 |
| EP1688161A1 (de) | 2006-08-09 |
| DK1807083T3 (da) | 2011-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE503482T1 (de) | Verwendung von pirlindol bei der behandlung von erkrankungen; die durch proliferation von t- lymphozyten und/oder hyperproliferation von keratinozyten gekennzeichnet sind; insbesondere atopische dermatitis und psoriasis | |
| DE602005010443D1 (de) | Kosmetische verwendung von polysaccharidverbindungen, die einen oder mehrere nicht-polymere siloxanpfropfzweige enthalten | |
| TNSN07272A1 (en) | Substituted bis aryl and heteroaryl compounds as selective 5ht 2a antagonists | |
| ATE544748T1 (de) | Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen | |
| CY1112790T1 (el) | Χρηση μαγιας σεληνιου στην αντιμετωπιση της νοσου αλτσχαιμερ | |
| MXPA05010630A (es) | Compuestos de benzopirano utiles para tratar estados inflamatorios. | |
| TW200628463A (en) | Heteroaryl compounds | |
| MXPA05012362A (es) | Yodopirazolilcarboxanilidas. | |
| CY1105748T1 (el) | Χρηση της ριλουζολης συνδυασμενης με καταλληλα εκδοχα και προσθετες ουσιες για τη θεραπεια ασθενειων που χαρακτηριζονται απο υπερβολικο πολλαπλασιασμο των κερατινοκυτταρων ιδιαιτερως της νευροδερματιτιδας και της ψωριασης | |
| NO20060230L (no) | Nye aminobenzofenonforbindelser | |
| NO20073574L (no) | Triazolsubstituerte aminobenzofenonforbindelser | |
| ATE494926T1 (de) | Neuartige p2x7r-antagonisten und ihre verwendung | |
| BR0306922A (pt) | N-pirazinil-fenilsulfonamidas e seu uso no tratamento de doenças mediadas por quimocina | |
| ATE530226T1 (de) | Verwendung von sinapinsäure in nicht- therapeutischen kosmetischen und/oder topischen zubereitungen | |
| ATE406353T1 (de) | Piperidin-derivaten und deren verwendung bei der behandlung von durch chemokinen oder h1 vermittelten krankheiten | |
| ATE518846T1 (de) | 2-aminooxazolderivate als für die behandlung von schmerzen geeignete trpvl-antagonisten | |
| NO20055741L (no) | Nye kjemiske forbindelser | |
| IL165505A0 (en) | 2-heteroaryl carboxamides | |
| EP4434980A4 (de) | Multifunktionelle verbindung zum abbau von btk-kinase sowie zusammensetzung und verwendung | |
| ATE524181T1 (de) | Verwendung von 1,4-bis (3-aminoalkyl) piperazin- derivaten bei der behandlung von neurodegenerativen erkrankungen | |
| ATE548310T1 (de) | Spaltfreudiges klebeband, seine verwendung und verwendung eines werkzeuges zu seiner herstellung | |
| ATE452134T1 (de) | Zur behandlung von auf eine modulation des dopamin-d3-rezeptors ansprechende erkrankungen geeignete 4-piperazinylpyrimidinverbindungen | |
| EA200701648A1 (ru) | Замещённые пирролы и имидазолы, содержащие их композиции, способ получения и применение | |
| DE60313803D1 (de) | Cathepsincysteinproteaseinhibitoren und deren verwendung zur behandlung von entzündungen und immunerkrankungen | |
| ATE547396T1 (de) | Dicycloalkylcarbamoyl-harnstoffe als glucokinase- aktivatoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1807083 Country of ref document: EP |